Clinical Trials Logo

CEBPA Double Mutation clinical trials

View clinical trials related to CEBPA Double Mutation.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04415008 Recruiting - Clinical trials for Acute Myeloid Leukemia

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

Start date: June 1, 2020
Phase: Phase 2
Study type: Interventional

Acute myeloid leukemia is a heterogenous hematological malignancy, characterized by different cytogenetic or molecular features. CEBPA double mutation acute myeloid leukemia (CEBPAdm AML)has favourite prognosis, especially in younger adult patients. But cumulative incidence of relapse of this group patients is still high, so the treatment options need to be optimized urgently.HAD(homoharringtonine(HHT)+cytarabine+daunorubicin) with intermediate dose cytarabine improved the survival of AML, especially in patients with CEBPA double mutation.